Medistim ASA (LON:0OCD)
London
· Delayed Price · Currency is GBP · Price in NOK 160.50
-5.00 (-3.02%)
At close: Apr 15, 2025
Medistim ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 556.16 | 521.11 | 486.26 | 417.82 | 356.21 | Upgrade
|
| Revenue Growth (YoY) | 6.73% | 7.17% | 16.38% | 17.30% | -0.20% | Upgrade
|
| Cost of Revenue | 113.68 | 112.28 | 106.49 | 97.11 | 76.58 | Upgrade
|
| Gross Profit | 442.48 | 408.83 | 379.78 | 320.7 | 279.63 | Upgrade
|
| Selling, General & Admin | 174.35 | 150.2 | 136.51 | 124.02 | 108.39 | Upgrade
|
| Other Operating Expenses | 112.55 | 103.53 | 78.73 | 62.27 | 52.61 | Upgrade
|
| Operating Expenses | 311.41 | 277.39 | 238.53 | 209.72 | 184.15 | Upgrade
|
| Operating Income | 131.08 | 131.44 | 141.25 | 110.99 | 95.48 | Upgrade
|
| Interest Expense | - | - | -0.12 | -0.18 | -0.15 | Upgrade
|
| Interest & Investment Income | 4.57 | 3.28 | 0.92 | 0.02 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.63 | 0.93 | 3.06 | -1.81 | -3.48 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.23 | -0.44 | 0.94 | -0.24 | -0.26 | Upgrade
|
| EBT Excluding Unusual Items | 134.25 | 135.21 | 146.05 | 108.78 | 91.61 | Upgrade
|
| Other Unusual Items | - | - | - | 5.29 | - | Upgrade
|
| Pretax Income | 134.25 | 135.21 | 146.05 | 114.07 | 91.61 | Upgrade
|
| Income Tax Expense | 30.41 | 31.39 | 32.08 | 23.17 | 22.22 | Upgrade
|
| Net Income | 103.83 | 103.82 | 113.97 | 90.9 | 69.39 | Upgrade
|
| Net Income to Common | 103.83 | 103.82 | 113.97 | 90.9 | 69.39 | Upgrade
|
| Net Income Growth | 0.01% | -8.91% | 25.38% | 31.00% | -1.31% | Upgrade
|
| Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | 0.10% | 0.10% | 0.15% | 0.07% | 0.13% | Upgrade
|
| EPS (Basic) | 5.67 | 5.68 | 6.25 | 4.99 | 3.81 | Upgrade
|
| EPS (Diluted) | 5.67 | 5.67 | 6.24 | 4.98 | 3.80 | Upgrade
|
| EPS Growth | -0.01% | -9.13% | 25.30% | 31.05% | -1.55% | Upgrade
|
| Free Cash Flow | 137.04 | 102.8 | 104.24 | 119.97 | 66.68 | Upgrade
|
| Free Cash Flow Per Share | 7.48 | 5.62 | 5.70 | 6.57 | 3.66 | Upgrade
|
| Dividend Per Share | 6.000 | 4.500 | 4.500 | 3.750 | 3.000 | Upgrade
|
| Dividend Growth | 33.33% | - | 20.00% | 25.00% | 9.09% | Upgrade
|
| Gross Margin | 79.56% | 78.45% | 78.10% | 76.76% | 78.50% | Upgrade
|
| Operating Margin | 23.57% | 25.22% | 29.05% | 26.56% | 26.81% | Upgrade
|
| Profit Margin | 18.67% | 19.92% | 23.44% | 21.76% | 19.48% | Upgrade
|
| Free Cash Flow Margin | 24.64% | 19.73% | 21.44% | 28.71% | 18.72% | Upgrade
|
| EBITDA | 146.8 | 146.72 | 157.45 | 127.26 | 105.06 | Upgrade
|
| EBITDA Margin | 26.39% | 28.16% | 32.38% | 30.46% | 29.49% | Upgrade
|
| D&A For EBITDA | 15.72 | 15.27 | 16.2 | 16.27 | 9.57 | Upgrade
|
| EBIT | 131.08 | 131.44 | 141.25 | 110.99 | 95.48 | Upgrade
|
| EBIT Margin | 23.57% | 25.22% | 29.05% | 26.56% | 26.81% | Upgrade
|
| Effective Tax Rate | 22.66% | 23.21% | 21.96% | 20.31% | 24.25% | Upgrade
|
| Revenue as Reported | 562.6 | 526.36 | 491.94 | 427.28 | 363.13 | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.